Key Points {#FPar1}
==========

COVID-19 is a syndrome of viral replication and a host inflammatory response.Tackling the immune response may be as important as addressing viral replication.Specific and non-specific immune modulators have the potential to inhibit cytokines and quell the cytokine storm.

Introduction {#Sec1}
============

Although the pathogenesis of COVID-19, the result of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still not completely understood, a proposed four-stage classification system of escalating phases represents a useful construct for a structured approach to clinical phenotyping, choice of therapy, and clinical outcome \[[@CR1], [@CR2]\]. Stage I (early infection) begins at the time of viral inoculation and establishment of infection. Patients may or may not manifest non-specific symptoms (i.e. malaise, fever, sore throat, dry cough), and treatment is often symptomatic. Stage II is characterized by hyperresponsiveness of the immune system. Patients develop viral pneumonia and possibly hypoxia, and markers of systemic inflammation are elevated. The third stage is characterized by a hypercoagulable state. Patients with hypoxia are likely to progress to stage IV, the most severe stage, where multiorgan failure occurs. Most patients also develop lymphopenia and pneumonia with bilateral infiltrations on chest computed tomography (CT) scan \[[@CR3]--[@CR5]\]. Systemic proinflammatory cytokines and biomarkers such as interleukin (IL)-1, IL-2, IL-6, and IL-7, tumor necrosis factor (TNF)-α, granulocyte--macrophage colony-stimulating factor (GM-CSF), macrophage inflammatory protein 1-α, C-reactive protein (CRP), ferritin, and D-dimer are significantly high in this stage \[[@CR4], [@CR6]\].

The presence of elevated proinflammatory cytokines in advanced stages of disease was also observed in prior epidemics, such as those caused by SARS-CoV and MERS-CoV, suggesting a cytokine release syndrome (CRS) or 'cytokine storm'-mediated immunopathology \[[@CR7]--[@CR9]\]. The cytokine dysregulation and influx of inflammatory myeloid cells can lead to lung infiltration and critical symptoms, including sepsis, shock, respiratory failure, acute respiratory distress syndrome (ARDS), multiorgan system dysfunction, and death \[[@CR10]\]. Since lymphopenia is often observed in early and late stages of COVID-19 patients, the CRS may likely be mediated by leukocytes other than T cells \[[@CR9]\]. The cytokine storm is thought to resemble secondary hemophagocytic lymph histiocytosis (sHLH) \[[@CR11]\]. The macrophage activation syndrome (MAS)-like pulmonary immunopathology characteristic of COVID-19, above and beyond the direct endothelial damage from SARS-CoV-2, may explain the high degree of micro- and macrothrombotic findings in this patient population \[[@CR12]\].

Cytokine storm, along with viral evasion of cellular immune responses, may play an equally important role in disease progression. Thus, tackling the immune response with immunomodulatory agents may be as important as addressing viral replication to prevent the progression to multiorgan dysfunction (Fig. [1](#Fig1){ref-type="fig"}). Herein, we discuss the role of specific and non-specific immunomodulating agents, including neutralizing monoclonal antibodies, corticosteroids, and other molecules in the management of severe COVID-19, and their impact on survival and clinical symptoms.Fig. 1Schematic representation of the immunomodulators' site of action. Hydroxychloroquine, azithromycin, statins, RAASi and their combinations have not been reliably shown to be of benefit in hospitalized patients with COVID-19, and therefore are represented here to define a potential pathophysiological target for therapy. This should not be seen as endorsement for use of such agents. The use of hydroxychloroquine and azithromycin in COVID-19 patients may be associated with harm. Whether such agents are beneficial in other stages of infection remains a matter of study.   Created with biorender.com. *Ang II* angiotensin II, *GM-CSF* granulocyte--macrophage colony-stimulating factor, *IFN* interferon, *IL* interleukin, *IL-6R* interleukin-6 receptor, *IVIG* intravenous immunoglobulin, *JAK* Janus kinase, *JAK-STAT* Janus kinase-signal transducer and activator of transcription, *MIP-1α* macrophage inflammatory protein 1-α, *MyD88* myeloid differentiation primary response 88, *NF-κB* nuclear factor-κB, *RAAS* renin--angiotensin--aldosterone system, *rhuGM-CSF* recombinant human granulocyte--macrophage colony-stimulating factor, *sIL-6R* soluble IL-6 receptor, *TLR* toll-like receptor, *TNF* tumor necrosis factor reserve

Methods of Literature Review {#Sec2}
============================

An English-language literature search was performed using PubMed and Google Scholar to identify relevant articles published through 8 July 2020. Search terms included 'coronavirus', 'immunology', 'cytokine storm', 'immunomodulators', 'pharmacology', 'severe acute respiratory syndrome 2', 'SARS-CoV-2', and 'COVID-19'. The authors of this current review included case reports, case series, review articles, and randomized controlled trials. Ongoing and planned clinical trials were identified using the search term 'COVID-19′ on the ClinicalTrials.gov website.

Immunomodulatory Agents {#Sec3}
=======================

Once a pathogen enters the body, it is addressed by two lines of defense: innate immunity and adaptive immunity (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR13]\]. Innate immunity encompasses a number of soluble and cell-based antimicrobial factors and is triggered very early after infection. Adaptive immunity, which consists of pathogen-specific antibody and T cells, develops later and contributes to both clearing of infection and immunity against subsequent infection. Innate and adaptive immunity work together to detect and eliminate pathogens. Immunomodulatory drugs can stimulate (immunostimulants), suppress (immunosuppressants) or modulate various aspects of the immune system, including both adaptive and innate immune systems \[[@CR14]\]. Immunostimulators are often prescribed to enhance the immune response against infectious diseases, however, morbidity and mortality in severe COVID-19 is associated with hyperinflammation \[[@CR15]\], and interfering with cytokine signaling using immunomodulatory strategies may significantly reduce hyperinflammation in these patients. The action of immunomodulators can be specific or non-specific \[[@CR13], [@CR14]\].Fig. 2The immune system is classically divided into innate and adaptive components. The innate immune system provides nonspecific resistance to pathogens, whereas adaptive immunity is characterized by antigen specificity and immunologic memory. Immunomodulators are drugs that either stimulate or suppress the immune system. The two immune systems, along with immunomodulators, work together to prevent and control infection. *CP* convalescent plasma, *IL* interleukin, *GM-CSF* granulocyte--macrophage colony-stimulating factor, *IVIG* intravenous immunoglobulin, *JAK* Janus kinase, *NK* natural killer, *RAASi* renin--angiotensin--aldosterone system inhibitors, *rhuGM-CSF* recombinant human granulocyte--macrophage colony-stimulating factor, *TNF* tumor necrosis factor

Specific Immune Modulators {#Sec4}
==========================

Anti-cytokines {#Sec5}
--------------

### Interleukin (IL)-1 Receptor Antagonists {#Sec6}

Anakinra is a recombinant human IL-1 receptor antagonist indicated for rheumatoid arthritis (RA) and cryopyrin-associated periodic syndromes \[[@CR16]\]. It works by inhibiting the proinflammatory cytokines IL-1α and IL-1β \[[@CR17]\]. In earlier studies, anakinra was shown to be effective in treating MAS, which presents as a fulminant cytokine storm \[[@CR18]\]. This may suggest a role for anakinra in combating CRS symptoms in COVID-19 patients. Re-analysis of data from a phase III randomized controlled trial revealed that IL-1 receptor blockade with anakinra was associated with significant improvement in survival of patients with sepsis \[[@CR19]\]. There are currently no published controlled clinical trials supporting the efficacy or safety of anakinra in treating COVID-19. In a small case-series of nine patients with moderate to severe COVID-19 pneumonia, the use of anakinra was well-tolerated and effective in improving clinical and biological markers \[[@CR20]\]. In a different cohort study on patients with severe COVID-19, anakinra decreased both the need for invasive mechanical ventilation in the intensive care unit, and mortality \[25% vs. 73%, hazard ratio (HR) 0.22, 95% confidence interval (CI) 0.11--0.41, *p* \< 0.0001\] \[[@CR21]\]. The efficacy of high-dose anakinra was evaluated in intensive care unit COVID-19 patients with a positive hemophagocytosis score (HScore) and diagnosed sHLH \[[@CR22]\]. The mortality was lower than previous series of patients with sHLH in sepsis, although three patients died. The use of anakinra was associated with less need for vasopressors, significantly improved pulmonary function, and lower HScore.

A phase III, randomized, open-label, multicenter trial (NCT04324021) evaluating the efficacy and safety of anakinra and emapalumab, an anti-interferon (IFN)-γ antibody, in the treatment of hyperinflammatory syndrome caused by the cytokine storm commenced on 2 April 2020 (NCT04324021). Although the subcutaneous formulation is the only US FDA-approved dosage form of anakinra \[[@CR16]\], the dosage form being investigated in the ongoing trial is by intravenous infusion \[[@CR20]\]. Other noncomparative, open-label studies underway in Greece (NCT04356366, NCT04339712) and Belgium (NCT04330638) are using the subcutaneous form.

### IL-6 Receptor Antagonists {#Sec7}

Abnormally high levels of IL-6 are an indicator of poor outcome in COVID-19 patients with pneumonia and ARDS \[[@CR23]\]. Tocilizumab (Actemra®) is a recombinant humanized anti-human IL-6 receptor monoclonal antibody that can specifically bind the membrane-bound IL-6 receptor (mIL6R) and soluble IL-6 receptor (sIL6R), thereby inhibiting signal transduction \[[@CR24]\]. Tocilizumab is currently FDA-approved for the management of RA, giant cell arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis \[[@CR24]\]. It is also approved for the management of chimeric antigen receptor (CAR) T-cell-induced CRS \[[@CR24]\], making it a possible therapeutic option for CRS of severely ill COVID-19 patients who have extensive lung lesions and high IL-6 levels \[[@CR25]\].

A single-arm Chinese investigation by Xu et al. included 21 severe or critical COVID-19 patients and showed that all patients who received tocilizumab demonstrated remarkable fever reduction within days following therapy, and a reduced need for supplemental oxygen was observed in 15 (75%) patients \[[@CR25]\]. The authors concluded that tocilizumab is an effective treatment in severely ill COVID-19 patients. Tocilizumab was administered as a single dose of 400 mg by intravenous infusion, with only three (14.2%) patients requiring an additional dose within 12 h of the first dose because of persistent fever. This dosing regimen was in agreement with the National Health Commission and State Administration of Traditional Chinese Medicine, which recommends a dose of 400 mg (4--8 mg/kg), and one additional administration after 12 h if ineffective, and a maximum single dose of 800 mg \[[@CR26]\]. Another Chinese retrospective, observational study by Luo et al. included 15 moderately to critically ill COVID-19 patients who received tocilizumab (80--600 mg per dose) in combination with methylprednisolone in 8 of the patients. Five patients received two or more doses of tocilizumab. Elevated CRP levels rapidly decreased in all patients following administration, and a gradual decrease in IL-6 levels was observed in patients who stabilized following tocilizumab administration. Three of the four critically ill patients who received a single dose died, suggesting that a repeated dose of tocilizumab may improve clinical outcomes \[[@CR27]\]. Furthermore, a single-center, retrospective, observational Italian study of 20 renal transplant recipients with SARS-CoV-2 pneumonia included six patients who received tocilizumab. Three (50%) of the patients experienced reduced oxygen requirements and two (33%) showed improved radiologic findings following administration, whereas two (33%) of the six tocilizumab-treated patients died \[[@CR28]\]. In the TESEO study, a large, multicenter, retrospective cohort study of 544 patients, the use of intravenous or subcutaneous tocilizumab was associated with reduced risk of mechanical ventilation and death (adjusted HR 0.61, 95% CI 0.40--0.92, *p* = 0.020) \[[@CR27]\]. The primary outcome was a composite of death or progression to invasive mechanical ventilation. At day 14 after hospital admission, 22.6% (95% CI 16.2--29.0) of the patients who received tocilizumab had the primary outcome, compared with 36.5% (95% CI 30.7--42.2) in those who received standard of care. Similar results were reported regardless of the route of tocilizumab administration.

There are multiple clinical trials planned or initiated using tocilizumab in COVID-19 patients in the US, China, and Europe. Interim results from CORIMUNO-TOCI (NCT04331808), an open-label, phase II, randomized clinical trial, showed that a significantly lower number of the patients in the tocilizumab arm achieved the primary outcome of need for ventilation, or death, at day 14. In China, a multicenter, randomized controlled trial evaluating the efficacy and safety of tocilizumab in 188 COVID-19 patients is ongoing \[[@CR29]\]. The 94 patients in the experimental arm will receive conventional therapy with tocilizumab, while the remaining 94 patients in the control arm will receive conventional therapy alone. Another randomized, double-blind, placebo-controlled phase III trial is taking place at a global level in the US, Canada, UK, and Europe (NCT04320615). The study will evaluate the safety and efficacy of tocilizumab in combination with standard of care compared with placebo in approximately 330 patients.

Another IL-6 receptor antagonist that may potentially combat CRS and pulmonary symptoms in severely ill patients is sarilumab (Kefzara^®^), which is indicated for the treatment of adult patients with moderately to severely active RA who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs \[[@CR30]\]. Although there are no known published clinical trials supporting the use of sarilumab in COVID-19 patients, it may have a similar effect to tocilizumab on the inflammatory response in severely ill COVID-19 patients. A US-based, phase II/III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of high- and low-dose intravenous sarilumab in hospitalized patients with severe COVID-19 is currently under way (NCT04315298). A preliminary analysis of the trial demonstrated that sarilumab was effective in critically ill (i.e. requiring mechanical ventilation or high-flow oxygenation, or required treatment in an intensive care unit) COVID-19 patients, but not in severely ill (i.e. did not require mechanical or high-flow oxygenation) patients. Accordingly, the phase III portion of the trial was narrowed to include only critically ill patients \[[@CR31]\].

### Janus Kinase Inhibitors {#Sec8}

By inhibiting the Janus kinase (JAK)-signal transducer and activator of transcription (JAK-STAT) pathway, JAK inhibitors are hypothesized to play a role in the management of CRS in severely ill COVID-19 patients \[[@CR32]\]. Ruxolitinib (Jakafi^®^) is a potent and selective oral inhibitor of both JAK1 and JAK2 protein kinases. It is indicated for intermediate- or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease \[[@CR33]\]. Ruxolitinib interrupts signaling downstream of multiple proinflammatory cytokines, which constitute the cytokine storm and increased activation of the JAK-STAT pathway \[[@CR32]\]. However, one concern about the use of these agents is the blockade of IFNα, a cytokine critical in defense against viruses \[[@CR34]\]. In addition, severe reactions after initiation of ruxolitinib were reported in two COVID-19 patients, and required drug discontinuation \[[@CR35]\]. Both patients developed cutaneous reactions with purpuras and a progressive decrease in hematocrit values, and one patient also developed thrombocytopenia and a deep-tissue infection. These adverse events may be due to the concomitant use of ritonavir, a CYP3A4 inhibitor, leading to an increase in ruxolitinib plasma concentrations. Thus, the role and safety of this type of JAK inhibitor in the management of inflammatory cytokine storm caused by COVID-19 is questionable.

There are currently no published clinical trials to support the use of ruxolitinib or other JAK inhibitors in COVID-19. Two ongoing phase III randomized clinical trials are evaluating the efficacy and safety of ruxolitinib plus standard of care, compared with standard-of-care therapy alone, in adult patients with COVID-19-associated cytokine storm (NCT04362137; RUXOCOVID), and in adults with COVID19-associated ARDS who require mechanical ventilation (NCT04377620; RUXCOVID-DEVENT). Additionally, open-label emergency Expanded Access Programs (EAP) for patients diagnosed with severe or very severe COVID-19 illness (NCT04337359) and patients with COVID-19-associated cytokine storm (NCT04355793) are underway.

Baricitinib (Olumiant^®^) is another JAK1 and JAK2 inhibitor that is predicted to have a dual effect of reducing both viral entry and inflammation in COVID-19 patients \[[@CR36]\]. Baricitinib might be preferred over other JAK-STAT signaling inhibitors, given its once-daily dosing and acceptable adverse effect profile \[[@CR37]\]. Additionally, its low plasma protein binding properties and minimal interaction with CYP enzymes and drug transporters allows for well-tolerated concomitant use of baricitinib with the direct-acting antivirals (e.g. remdesivir) and other drugs \[[@CR38]\]. However, the use of baricitinib is associated with increased thromboembolic events, which is concerning given that COVID-19 patients are at risk of developing these events \[[@CR39]\]. In an Italian open-label study of 12 patients with moderate COVID-19 pneumonia \[[@CR40]\], baricitinib therapy combined with lopinavir/ritonavir was associated with significant improvement in clinical and laboratory parameters, and none of the patients required intensive care unit support, however, the study was limited by its small sample size and open-label design. An open-label, multicenter, adaptive phase II/III study to evaluate the safety and efficacy of baricitinib in hospitalized patients with COVID-19 has commenced (NCT04340232). Other clinical trials are evaluating baricitinib in combination with or without an antiviral agent for the treatment of COVID-19 (NCT04346147, NCT04320277, NCT04345289, NCT04321993). Notably, baricitinib is included as an arm in the National Institute of Allergy and Infectious Diseases' (NIAID) phase III adaptive COVID-19 treatment trial \[[@CR41]\]. Currently, the National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel recommends against the use of JAK inhibitors for the treatment of COVID19 except in the context of a clinical trial, in part because the broad immunosuppressive effect of JAK inhibitors outweighs the potential for benefit \[[@CR42]\]. An NIH-sponsored randomized, controlled trial (Adaptive COVID-19 Treatment Trial 2) combining the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib is currently underway and will investigate whether adding an anti-inflammatory agent to remdesivir can provide additional benefit for patients \[[@CR43]\]. Patients will receive either the combination or remdesivir alone, the latter of which was the focus of the Adaptive COVID-19 Treatment Trial. This combination may be able to control the viral infection as well as reduce the immune system reaction.

### Anti-tumor Necrosis Factor-α {#Sec9}

TNFα plays a key role in almost all acute inflammatory reactions by inducing oxidative stress and inflammation. TNFα is mainly produced by macrophages, although it can also be produced by monocytes, B cells, and other tissues. Activating TNFα also results in the production of IL-1 and IL-6 \[[@CR44]\]. An excess amount of TNF is found in the plasma and tissues of patients with COVID-19 \[[@CR45]\], which are reported to be produced by the high numbers of monocytes expressing TNFα \[[@CR46]\]. It has been reported that the binding of SARS-CoV-2 to angiotensin-converting enzyme (ACE)-2 induces TNFα-converting enzyme (TACE)-dependent shedding of the ACE2 ectodomain, which facilitates viral entry and causes tissue damage through TNFα production \[[@CR47]\].

Anti-TNFα therapy, such as adalimumab or infliximab, is used in the management of several autoimmune inflammatory diseases such as RA, inflammatory bowel disease, and ankylosing spondylitis \[[@CR48]\]. Experimental studies suggest a potential rationale for use of anti-TNF therapy in viral pneumonia \[[@CR46]\]. It has been proposed that a single infusion of anti-TNFα antibody can significantly reduce the amount of TNF in the blood \[[@CR49]\], suggesting a possible anti-inflammatory benefit in COVID-19. Besides its classical effect on TNFα inhibition, anti-TNFα may also induce the downregulation of ACE2 expression and shedding \[[@CR47], [@CR50]\]. However, there is also concern that anti-TNFα therapy might increase the risk of bacterial or fungal superinfections \[[@CR49]\].

Their effectiveness, wide availability, various dosage forms, and safety profile make anti-TNFα antibodies, particularly adalimumab, a promising therapeutic option for mitigating the inflammatory stage in COVID-19. It may be reasonable to initiate anti-TNFα therapy as early as possible \[[@CR49]\], as delayed treatment may limit the effectiveness of these agents. The potential role of anti-TNFα therapy warrants consideration and should be investigated as a potential therapy to prevent progression to more advanced stages. A Chinese study evaluating adalimumab in COVID-19 infection is underway (ChiCTR2000030089). A prospective, single center, phase II trial evaluating the efficacy of infliximab or infliximab-abda in hospitalized adult patients with severe or critical COVID-19 has also commenced (NCT04425538).

Granulocyte--Macrophage Colony-Stimulating Factor {#Sec10}
-------------------------------------------------

GM-CSF is a pleiotropic growth factor and proinflammatory cytokine that is released from alveolar epithelial cells and has been shown to drive pulmonary host defense function against pathogens, including the influenza virus \[[@CR51]\]. Besides their role in inducing proliferation and differentiation of macrophages and dendritic cells \[[@CR52]\], GM-CSF stimulates epithelial repair, including epithelial proliferation and barrier restoration, through direct interaction with the alveolar epithelial cells, thereby providing a lung-protective effect \[[@CR51]\]. In patients with ARDS, elevated GM-CSF levels in the bronchoalveolar lavage fluid (BALF) are associated with antiapoptotic effects and improved epithelial barrier integrity and survival \[[@CR53], [@CR54]\]. Studies have shown that GM-CSF can have a dual role as a proinflammatory and regulatory cytokine, depending on the dose and presence of other relevant cytokines \[[@CR55]\]. The proinflammatory signal of GM-CSF can induce macrophages to elicit an immune response via a positive feedback mechanism that can ultimately result in tissue damage. Recent studies on COVID-19 patients show that increased levels of GM-CSF contribute to the immunopathology of ARDS \[[@CR4], [@CR56]\].

Given their effects in driving immune functions, GM-CSFs may confer benefit to COVID-19 patients by providing the stimulus to restore pulmonary hemostasis and repair \[[@CR57]\]. Previous studies have shown that a low-dose of intravenous GM-CSF in severely septic adult patients with respiratory dysfunction improves oxygenation and gas exchange \[[@CR58]\], although it failed to improve survival and ventilation parameters in adult patients with acute lung injury in another trial \[[@CR57]\]. There is evidence to suggest that the application of GM-CSF by the inhalation route may represent an effective strategy for pneumonia-associated ARDS \[[@CR52]\]. Sargramostim (Leukine^®^), the only FDA-approved GM-CSF, is a yeast-derived recombinant humanized GM-CSF (rhuGM-CSF) that is currently being investigated as an adjuvant therapy for the management of COVID-19 associated with acute hypoxic respiratory failure and ARDS (NCT04326920). Patients will be randomized to receive nebulized sargramostim 125 μg twice daily for 5 days in addition to standard of care, or standard-of-care treatment alone. Patients in the experimental arm who progress to ARDS requiring initiation of invasive mechanical ventilation within the 5-day period will be switched to intravenous sargramostim 125 μg/m^2^ body surface area until the 5-day period is complete. Since high levels of GM-CSF in the alveoli should be achieved for virus clearance and acute lung injury, as well as ARDS treatment \[[@CR52]\], it is important that GM-CSF be investigated via the inhaled route \[[@CR51]\].

On the other hand, GM-CSF levels are upregulated in the serum of COVID-19 patients with a cytokine storm \[[@CR59], [@CR60]\]. Since GM-CSF functions upstream of other proinflammatory cytokines and chemokines, GM-CSF-targeted immunomodulation may be a viable therapy for this stage of the disease. One potential agent is gimsilumab, a clinical stage, fully human monoclonal antibody targeting GM-CSF. A randomized, double-blind, placebo-controlled, multicenter pivotal trial evaluating the role of intravenous gimsilumab in the prevention and treatment of ARDS and mortality in COVID-19 is underway (NCT04351243). A single-arm, open-label pilot study will study the role of TJM2, a monoclonal antibody capable of neutralizing GM-CSF, in decreasing cytokine levels in severe SARS-CoV-2 patients \[[@CR61]\]. Other anti-GM-CSF agents, including lenzilumab (NCT04351152) and namilumab \[[@CR62]\], are also being evaluated.

Convalescent Plasma {#Sec11}
-------------------

There is evidence to suggest that convalescent plasma transfusion from patients who have recovered from the infection with a high neutralizing antibody titer (NAT) may provide short-term passive immunity that could be beneficial in the prevention of infection or as a treatment strategy for patients with COVID-19 \[[@CR63]--[@CR68]\]. Convalescent plasma has previously been used to improve the survival rate of patients with SARS, Ebola, H1N1, and MERS, all of which showed variable outcomes \[[@CR66], [@CR69], [@CR70]\].

In a study of 93 patients with severe H1N1 2009 infection requiring intensive care, 20 (21.5%) of whom received convalescent plasma therapy, the use of plasma was associated with a reduction in the viral load on days 3, 5, and 7 (*p* \< 0.05), cytokine and chemokine levels (*p* \< 0.05), and mortality (20% vs. 54.8%; *p* = 0.011) \[[@CR71]\]. A systematic review by Mair-Jenkins et al. reported a statistically significant 75% reduction in the odds of mortality in SARS and severe influenza patients who received convalescent plasma \[[@CR72]\]. SARS patients who received convalescent plasma within 14 days after the onset of symptoms manifested better outcomes than those who received treatment later in the disease course \[[@CR63], [@CR64], [@CR69], [@CR72]\]. Serious adverse events or complications were not reported, however, the studies were of low quality and mainly uncontrolled.

Shen et al. reported the first study of five critically ill COVID-19 patients with ARDS requiring mechanical ventilation who received two consecutive convalescent plasma transfusions containing high-titer neutralizing antibodies (NAT of 80--480) in conjunction with continued methylprednisolone and antiviral treatment \[[@CR73]\]. Before transfusion, patients displayed continuously high viral load despite antiviral treatment for at least 10 days. Plasma transfusion was administered 10--22 days after admission. All patients eventually improved clinically: in four patients, ARDS resolved 12 days following transfusion, three patients were weaned from mechanical ventilation within 2 weeks, the body temperature of four patients normalized within 3 days, Sequential Organ Failure Assessment (SOFA) score decreased, P~AO2~/F~IO2~ increased within 12 days, viral loads decreased and became negative within 12 days after transfusion, and SARS-CoV-2-specific enzyme-linked immunosorbent assay (ELISA) and NATs increased. In another pilot study \[[@CR74]\], 10 adults with severe COVID-19 received a single transfusion of COVID-19 convalescent plasma (NAT of 1:640 or greater) in addition to standard care, all patients received monotherapy or combination antiviral therapy, and six patients also received methylprednisolone. The mean time from onset of illness to transfusion was 16.5 days (interquartile range \[IQR\] 11.0--19.3). COVID-19 symptoms, such as fever, cough, shortness of breath, and chest pain improved in all patients within 1--3 days following transfusion. Patients showed variable degrees of improvement on chest CT, where those transfused before 14 days post onset of illness showed better improvement. NAT increased in five patients after the transfusion, but remained the same in four patients. Reverse transcription polymerase chain reaction (RT-PCR) tests for SARS-CoV-2 RNA were positive in seven patients before transfusion. After transfusion, SARS-CoV-2 RNA was undetectable in three patients on day 2, three patients on day 3, and one patient on day 6. More recently, an FDA-initiated, national, multicenter, open-label EAP study (NCT04338360) in 5000 hospitalized adults who were at high risk of progressing to severe or life-threatening COVID-19, showed that transfusion of ABO-compatible COVID-19 convalescent plasma (200--500 mL) was well-tolerated \[[@CR75]\]. Fewer than 1% of patients manifested major adverse events such as transfusion-associated circulatory overload, transfusion-related acute lung injury (TRALI), and severe allergic transfusion reaction, and only two of these events were clinically judged as certainly associated with the transfusion.

On the other hand, a Chinese open-label, multicenter, randomized controlled study evaluating the efficacy and safety of convalescent plasma therapy on 103 COVID-19 patients with severe or life-threatening disease found no significant difference in time to clinical improvement within 28 days, mortality, or time to hospital discharge \[[@CR76]\]. Clinical improvement within 28 days was only observed in the subgroup of patients with severe COVID-19 disease (HR 2.15, 95% CI 1.07--4.32, *p* = 0.03). However, most patients received convalescent plasma treatment at least 14 days after symptom onset, further suggesting that convalescent plasma therapy should be initiated earlier. Major adverse events were not observed, except for two patients who experienced adverse events within hours following transfusion that were managed with supportive care.

Non-specific Immune Modulators {#Sec12}
==============================

Human Immunoglobulin {#Sec13}
--------------------

Intravenous immunoglobulin (IVIG) contains immunoglobulin G of all subclasses obtained from pooled human plasma \[[@CR77]\]. IVIG has been used to provide immunity to viral infections \[[@CR78]\], including SARS, although the benefits of the treatment were inconclusive and some cases of thromboembolic complications were reported \[[@CR79], [@CR80]\]. IVIG is different from hyperimmune globulin from convalescent plasma, wherein the plasma is prepared from the plasma of donors with high antibody titers to specific pathogens \[[@CR81]\]. The mechanisms of action of IVIG are complex, and several mechanisms might account for its therapeutic benefit \[[@CR82]\]. IVIG can inhibit the activation and functions of various innate immune cells, and can neutralize activated complement components. It also impacts the adaptive immune system by modulating B-cell functions and plasma cells, regulating regulatory T cells and effector T cells such as T-helper (Th) 1 and Th17 subsets, and inhibiting inflammatory cytokines. It has also been proposed that IVIG can exert anti-inflammatory action by saturating Fcγ receptor binding, and binding to antiviral antibodies and proinflammatory cytokines \[[@CR81]\].

Cao et al. reported on three patients with severe COVID-19 who received high-dose IVIG at a dose of 0.3--0.5 g/kg/day for 5 days \[[@CR83]\]. All patients clinically improved shortly after the administration, normal body temperature was achieved in 1--2 days and respiratory rate improved in 3--5 days. These results are in line with a retrospective study of 58 severe to critically ill COVID-19 patients \[[@CR84]\]. The study reported a statistically significant difference in 28-day mortality between patients who received IVIG adjuvant therapy for COVID-19 pneumonia within 48 h of admission compared with those who received IVIG after 48 h (23.3% vs. 57.1%, *p* = 0.009). Thus, as with convalescent plasma, earlier initiation of therapy is encouraged. In spite of this, a different retrospective study of 325 severe or critical COVID-19 patients reported no difference in 28-day or 60-day mortality between patients who were treated with IVIG and those who were not (<https://www.medrxiv.org/content/10.1101/2020.04.11.20061739v2.full.pdf>).

Several randomized controlled trials evaluating the efficacy of IVIG therapy in severe COVID-19 are underway (NCT04350580, NCT04381858, NCT04261426). Both the NIH COVID-19 Treatment Guidelines Panel and the Surviving Sepsis Campaign COVID19 subcommittee do not recommend the use of commercially available IVIG (i.e. non-SARS-CoV-2-specific IVIG) for the treatment of COVID-19, in part because the current IVIG preparations are not likely to contain SARS-CoV-2 antibodies \[[@CR42], [@CR85]\]. IVIG benefits observed from current products can be due to anti-inflammatory mechanisms. It is likely that newly manufactured commercial IVIG preparations may contain antibodies against COVID-19, although this would depend on donor demographics.

Corticosteroids {#Sec14}
---------------

Corticosteroids have potent anti-inflammatory and antifibrotic properties, which theoretically could have a role in suppressing lung inflammation, particularly in the advanced stages of the disease \[[@CR86]\]. The debate regarding the use of corticosteroids in COVID-19 patients is far from conclusive. Low doses of corticosteroids downregulate proinflammatory cytokine transcription, consequently preventing an extended cytokine response and accelerating the resolution of pulmonary and systemic inflammation in pneumonia \[[@CR87]\]. Additionally, corticosteroids may help improve the dysregulated immune response caused by sepsis \[[@CR88]\], a possible complication of COVID-19, and can increase blood pressure in hypotensive patients \[[@CR89]\]. However, the use of corticosteroids can inhibit immune response, reduce pathogen clearance, and provoke viral replication \[[@CR86], [@CR90]\]. Thus, it might be reasonable to use corticosteroids in severe cases of COVID-19 with ARDS, providing that a low dose (≤ 0.5--1 mg/kg/day of methylprednisolone or equivalent) and short duration (≤ 7 days) are used \[[@CR26], [@CR85], [@CR91], [@CR92]\].

Earlier studies have shown that corticosteroid use in patients with SARS, MERS, and influenza was associated with no survival benefit and possible harm. Patients with SARS receiving corticosteroids reported adverse events such as avascular necrosis, psychosis, diabetes, and delayed viral clearance \[[@CR78]\]. Influenza patients manifest a higher risk of mortality and secondary infections with corticosteroids \[[@CR93]\]. In MERS patients, corticosteroids delayed lower respiratory tract clearance of MERS-CoV, although no effect on mortality was reported \[[@CR94]\]. Clinicians should balance the potential adverse effects of corticosteroids with the potential effects of prolonged coronavirus shedding.

Currently, the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) do not recommend the routine use of systemic corticosteroids for treatment of viral pneumonia unless indicated for another reason, such as asthma or chronic obstructive pulmonary disease exacerbation, or refractory septic shock \[[@CR95], [@CR96]\]. The Surviving Sepsis Campaign COVID-19 subcommittee recommends against the routine use of systemic corticosteroids in mechanically ventilated adults with COVID-19 and respiratory failure (without ARDS), although this is a weak and poorly substantiated recommendation \[[@CR85]\]. However, these recommendations may be amended based on preliminary results from the RECOVERY trial, which showed that dexamethasone reduces mortality among COVID-19 patients with severe respiratory complications \[[@CR97]\]. Low-dose dexamethasone (6 mg once daily, orally or intravenously) for 10 days reduced deaths by one-third in patients on mechanical ventilation \[rate ratio (RR) 0.65, 95% CI 0.48--0.88; *p* = 0.0003\] and by one-fifth in patients receiving oxygen only (RR 0.80, 95% CI 0.67--0.96; *p* = 0.0021); however, no benefit was reported in patients with milder symptoms (i.e. not requiring respiratory support). Prior to these findings, a multicenter, randomized controlled trial (DEXA-ARDS) studied the effects of intravenous dexamethasone at a dose of 20 mg once daily on days 1--5, followed by 10 mg once daily on days 6--10 in non-COVID-19 patients with moderate-to-severe ARDS receiving lung-protective mechanical ventilation \[[@CR98]\]. Compared with those receiving conventional treatment, the addition of dexamethasone to the therapy regimen lead to a reduction in mechanical ventilation duration (between-group difference of 4.8 days, 95% CI 2.57--7.03, *p* \< 0.0001), and in overall mortality at day 60 (between-group difference --15.3%, 95% CI − 25.9 to − 4.9; *p* = 0.0047). Accordingly, a multicenter, randomized, controlled, open-label trial (DEXA-COVID19) involving mechanically ventilated adult patients with ARDS with confirmed COVID-19 infection has commenced (NCT04325061). Compared with methylprednisolone, dexamethasone has less mineralocorticoid activity and is less likely to cause sodium and fluid retention, a concern in this patient population \[[@CR90]\].

The use of methylprednisolone in severe COVID-19 patients was evaluated in several retrospective, observational studies. Wang et al. showed that in 46 patients with confirmed severe COVID-19 pneumonia that progressed to acute respiratory failure, the use of methylprednisolone 1--2 mg/kg daily intravenously for 5--7 days in 26 patients was associated with a shorter average number of days to fever resolution (2.06 ± 0.28 vs. 5.29 ± 0.70; *p* = 0.010), faster improvement of SpO~2~, and lower number of days on supplemental oxygen therapy \[8.2 days (IQR 7.0--10.3) vs. 13.5 days (IQR 10.3--16); *p* \< 0.001\] \[[@CR99]\]. Death occurred in three patients during hospitalization, two of whom received methylprednisolone. Wu et al. showed that treatment with methylprednisolone decreased the risk of death (HR 0.38, 95% CI 0.20--0.72, *p* = 0.003) among patients with ARDS \[[@CR6]\]. Higher doses of methylprednisolone have been recommended for managing the cytokine storm: methylprednisolone 60--125 mg every 6 h for up to 3 days, followed by dose tapering when CRP levels begin to decline \[[@CR90]\].

Interferons {#Sec15}
-----------

IFNs are cytokines that play a key factor in reducing viral multiplication and modulating host immune response against viral infection \[[@CR100]\]. They consist of the ubiquitous α and β subtypes. IFNs are released by plasmacytoid dendritic cells during a viral infection \[[@CR100]\]. IFN treatment has been studied against MERS-CoV and SARS-CoV \[[@CR78]\]. Due to their nonspecific antiviral effects, IFNs are mainly tested in combination with other agents, such lopinavir/ritonavir, ribavirin, remdesivir, corticosteroids, or IFNγ \[[@CR100]\]. When IFNs bind to their receptors, they activate IFN-stimulated genes, which play an important role in inflammation, signaling, and immunomodulation \[[@CR100]\]. IFNs also sensitize human cells to viral proteins to prevent viral fusion or egress \[[@CR100]\]. In vitro studies suggest that SARS-CoV-2 may be more sensitive to IFN than other coronaviruses \[[@CR101]\]. While INFs were shown to be efficient in in vitro and animal models, they did not demonstrate a beneficial effect in patients with SARS \[[@CR102]\].

A 2003 open-label, uncontrolled study of 22 SARS patients, 9 of whom received corticosteroids in combination with INF alfacon-1, showed that patients who received this combination were less likely to be admitted to the intensive care unit (11.1% vs. 38.5%), had a shorter time to 50% resolution of lung radiographic abnormalities (4 days vs. 9 days; *p* = 0.001), and had better oxygen saturation (10 days vs. 16 days; *p* = 0.02) compared with SARS patients who received corticosteroids alone \[[@CR103]\]. Another retrospective cohort study of 44 patients investigated the use of ribavirin and INFα-2a compared with ribavirin alone for the management of severe MERS. The study reported both a 14-day and 28-day survival advantage in favor of the combination (70% vs. 29%, *p* = 0.004 at 14 days; 30% vs. 17%, *p* = 0.054 at 28 days) \[[@CR104]\].

INFs are being investigated for use in nebulized form (IFNα-2b) or as subcutaneous injections (INFβ-1b) for the management of COVID-19 (NCT04293887, NCT04350281). Clinical trials evaluating subcutaneous peginterferon lambda-1a for treatment (e.g. NCT04354259, NCT04388709) and postexposure prophylaxis (e.g. NCT04344600) of SARS-CoV-2 infection are also underway. A multicenter, randomized, prospective study on pediatric patients with respiratory syncytial virus investigated the use of nebulized INFα-1b compared with the subcutaneous injection. The study revealed that the nebulized form has a faster onset of action, a direct action on the mucosal epithelial cells in the lungs, less systemic adverse effects, and is less invasive to the pediatric population compared with the subcutaneous form \[[@CR105]\].

Recently, a multicenter, prospective, open-label, randomized, phase II trial included 127 adult patients with COVID-19 who received triple antiviral therapy of lopinavir/ritonavir, ribavirin, and nebulized IFNβ-1b \[[@CR106]\]. The use of early triple antiviral therapy was well-tolerated and superior to lopinavir/ritonavir alone in alleviating symptoms \[defined as a national early warning score 2 (NEWS2) of 0 (4 days vs. 8 days; HR 3.92, 95% CI 1.66--9.23; *p* \< 0.0001) and a SOFA score of 0 (3.0 days vs. 8.0 days; HR 1.89, 95% CI 1.03--3.49; *p* = 0.041)\] and in shortening hospital stay (9.0 days vs. 14.5 days; HR 2.72, 95% CI 1.2--6.13; *p* = 0.016). In addition, the combination group had a significantly shorter median time from treatment initiation to negative nasopharyngeal swab (7 days vs. 12 days; HR 4.37, 95% CI 1.86--10.24; *p* = 0.0010), suggesting that the triple antiviral therapy could shorten the duration of viral shedding. Additionally, in a retrospective study of 77 hospitalized adults with moderate COVID-19 disease who received aerosolized IFNα-2b (5 million units twice daily; *n* = 7), umifenovir (*n* = 24), or both drugs (*n* = 46), the time from symptom onset to negative RT-PCR result in the throat swab was shorter in the arm receiving IFNα-2b alone or in combination with umifenovir compared with those receiving umifenovir alone \[[@CR107]\], however, the study was limited by its small sample size, nonrandomized design, and dissimilar patient demographics and characteristics.

Miscellaneous/Inadvertent Immunomodulators {#Sec16}
==========================================

Statins {#Sec17}
-------

Besides their role in cardiovascular risk reduction, statins are reported to play a role in protecting the innate immune response to COVID-19 \[[@CR108]\]. The Massachusetts General Hospital guide for critically ill patients with COVID-19 advocates for the consideration of using statins, particularly in patients who are admitted to the intensive care unit \[[@CR109]\]. Since inflammation plays an important role in more severe manifestations of COVID-19, the anti-inflammatory properties of statins might potentially be useful \[[@CR110]\]. In experimental studies, statins have been shown to decrease inflammation \[[@CR111]\] and blunt the production of proinflammatory cytokines, including CRP and IL-6 \[[@CR111]\]. In addition, statins have direct beneficial effects that lead to decreased pulmonary vascular injury and ultimately decreased lung injury \[[@CR111]\]. However, these findings were reported in in vitro and animal studies that are generally performed in response to bacterial infections, and these effects have not been validated in humans.

Infection with SARS-CoV results in increased induction of the myeloid differentiation primary response 88 (MyD88) gene, which activates the nuclear factor (NF)-kB pathway and induces inflammation \[[@CR112]\]. Consequently, IFN-I is also reduced \[[@CR113]\]. In mice, inhibition of NF-kB is associated with a reduction in inflammation and lung pathology and increased mouse survival after SARS-CoV infection \[[@CR113]\]. Overexpression or underexpression of the MyD888 gene can increase the vulnerability to infection and mortality from SARS-like coronaviruses \[[@CR114], [@CR115]\]. While statins do inhibit the MyD88 pathway, they tend to preserve MyD88 levels during hypoxia and under stress, which may confer a protective effect in COVID-19 patients \[[@CR116]\].

In a multihospital retrospective cohort study of 2746 patients describing the prevalence of myocardial injury in COVID-19 patients, Lala et al. reported that statins have a protective effect and were associated with improved survival (HR 0.57, 95% CI 0.47--0.69) \[[@CR117]\]. While statins have a firmly established benefit in the context of myocardial injury, clinical trials demonstrating whether statins confer an anti-inflammatory effect or allow for improvement of endothelial dysfunction in COVID-19 are warranted. The beneficial effects of statins on COVID-19-related clinical symptoms were also described in a different retrospective multicenter cohort study \[[@CR118]\]. The study reported a statistically significant association between statin use and asymptomatic status, defined as having no disease symptoms in the entire study duration while testing positive on PCR (unadjusted odds ratio 2.91, 95% CI 1.27--6.71, *p* = 0.011). Serious COVID-19 symptoms were observed in 19% (6/31) of patients taking a statin compared with 25% (31/123) in those not taking a statin, although this finding was not statistically significant. Although not statistically significant, six of eight patients (75%) taking an ACE inhibitor (ACEi) or angiotensin II receptor blocker (ARB) and statin concomitantly remained asymptomatic throughout the duration of the study, which may suggest that this combination may have an additive beneficial effect on symptoms and clinical outcomes. Patients with confirmed or suspected COVID-19 who have an appropriate indication for statin use should continue or initiate therapy. However, if a COVID-19 patient does not have a cardiovascular indication for a statin, it might not be reasonable to commence therapy unless it is part of a clinical trial.

Renin--Angiotensin--Aldosterone System Inhibitors {#Sec18}
-------------------------------------------------

The renin--angiotensin--aldosterone system (RAAS) inhibitors, ACEi and ARB, confer potent dual effects, not only as cardiovascular protective therapies but also as anti-inflammatory and immunomodulatory agents \[[@CR119]\]. ACE2, the enzyme that converts angiotensin (Ang) I to Ang II, is expressed near the surface of human epithelial cells throughout the body, including the lungs \[[@CR120]\]. ACE2 receptors are the human cell entry points for SARS-CoV-2 \[[@CR120]\]. It was shown with SAR-CoV-1 that binding to ACE2 led to its downregulation and increased Ang II \[[@CR120]\]. There is a theoretical risk that ACEIs and ARBs can increase SARS-CoV-2 attachment by upregulating ACE2 \[[@CR121]\], although this was not substantiated by any human data and is an urgent research priority.

There is opposing evidence that being placed on an RAAS inhibitor could reduce the severity of lung injury in some viral pneumonias \[[@CR122]\]. ACEi and ARB block the downstream effects of Ang II. Notably, Ang II is known to foster inflammation, oxidation, vasoconstriction, and fibrosis \[[@CR123]\]. Therefore, a pharmacological agent that inhibits the production of Ang II could be beneficial for preventing lung injury and improving systemic health. Additionally, ACEi and ARB have a secondary effect of increasing ACE2 expression. ACE2 catalyzes the conversion of Ang II to Ang 1--7, which binds to the Mas receptor (MasR), leading to vasodilation and anti-inflammatory, antioxidant and antiapoptotic effects \[[@CR123]\].

A large, observational study analyzed the electronic health records of 12,594 patients in New York City who were tested for SARS-CoV-2 \[[@CR124]\], 5894 of these patients tested positive for the virus. A history of hypertension was described in 4357 patients (34.6%), of whom 2573 (59.1%) had a positive test, and 634 (24.6%) COVID-19-positive patients had severe illness. There was no difference in the likelihood of a positive test for SARS-CoV-2 between patients treated with an antihypertensive agent, including an ACEi or ARB, and matched untreated patients. There was also no difference in the likelihood of severe COVID-19 disease between patients treated with an antihypertensive agent and untreated patients. In line with these findings, a large Italian population-based case--control study of 6272 patients with confirmed SAR-CoV-2 infection revealed that there is no evidence that the use an ACEi or ARB affected the risk of COVID-19, severity of the clinical manifestations, or the course of infection \[[@CR125]\]. While the use of an ACEi or ARB was more commonly used in patients with COVID-19 than in controls, this was due to the higher prevalence of cardiovascular disease in these patients. Both of these large studies demonstrated that the use of an ACEi and ARB is not associated with an increased risk of infection with SARS-CoV-2. Thus, these agents should not be discontinued, unless the drugs cannot be tolerated due to hemodynamic instability \[[@CR126]\]. If a COVID-19 patient has an indication for these agents, therapy should be started or continued.

Macrolides {#Sec19}
----------

Macrolides, such as azithromycin and clarithromycin, are antibiotics with immunomodulatory and anti-inflammatory effects \[[@CR127]--[@CR134]\]. It was demonstrated that macrolides downregulate proinflammatory cytokines, although the exact mechanisms of these effects are not fully illuminated. Azithromycin has been used as an adjunctive therapy to provide antibacterial and potential immunomodulatory effects in the treatment of viral respiratory tract infections, including influenza \[[@CR133], [@CR135]\], and other respiratory conditions, such as ARDS \[[@CR128], [@CR129]\]. In a retrospective cohort study by Kawamura et al., patients with moderate or severe ARDS who received adjunctive azithromycin manifested a significant improvement in 90-day survival \[[@CR129]\]. In contrast, another retrospective cohort study in critically ill MERS patients indicated that macrolide therapy is not associated with a reduction in 90-day mortality rates or MERS-CoV RNA clearance \[[@CR132]\]. Thus, current data are insufficient to draw any firm conclusions about the benefits of adjunctive azithromycin in COVID-19 patients. Furthermore, this antibiotic is known to prolong the QT interval and potentially increase the risk of sudden cardiac death \[[@CR136]\], which is more of a concern for non-monitored outpatients receiving this therapy in combination with other QT-prolonging therapies.

Hydroxychloroquine and Chloroquine {#Sec20}
----------------------------------

It has been postulated that hydroxychloroquine and chloroquine exhibit immunomodulatory effects that theoretically may confer an anti-inflammatory response in patients with viral infections \[[@CR137]--[@CR140]\]. These drugs can reduce cytokine production, especially IL-1 and IL-6, and inhibit toll-like receptor signaling \[[@CR141], [@CR142]\]. A multicenter, parallel, open-label, randomized trial indicated the potentially beneficial anti-inflammatory effect of hydroxychloroquine in patients with COVID-19 \[[@CR143]\]. While adding hydroxychloroquine to the standard of care did not increase virus response, it did accelerate the alleviation of clinical symptoms, conceivably by reducing inflammation and recovery of lymphopenia. Symptomatic patients with elevated CRP and/or lymphopenia are the most likely COVID-19 patients to benefit from hydroxychloroquine. If these findings are confirmed in larger studies, hydroxychloroquine may be indicated to decrease the risk of progressive COVID-19 illness in patients, although this must await properly performed trials. However, as with azithromycin, this agent also prolongs the QT interval, and the combination of hydroxychloroquine and azithromycin could produce additive and potentially dangerous QT prolongation \[[@CR144]\].

More recently, an observational study by Geleris et al. \[[@CR145]\] analyzed data of 1376 patients who received hydroxychloroquine, 811 (58.9%) received hydroxychloroquine and 565 (41.1%) did not. The primary endpoint was the time from study baseline to intubation or death. The primary endpoint developed in 346 patients (25.1%), and there was no significant association between hydroxychloroquine use and the composite primary endpoint (HR 1.04, 95% CI 0.82--1.32). A multicentered, double-blind, placebo-controlled trial by Boulware et al. \[[@CR146]\] evaluated the use of hydroxychloroquine as a potential agent for post-exposure prophylaxis in 821 asymptomatic adults with occupational or household exposure, 66% were healthcare workers. The primary outcome was to identify new COVID-19 infections between patients who received hydroxychloroquine or placebo. Within 4 days of exposure, patients were randomized to either a 5-day regimen of hydroxychloroquine or placebo. While there were slightly fewer infections in the hydroxychloroquine arm (11.8% vs. 14.3%), the difference was not statistically significant (95% CI − 7.0 to 2.2; *p* = 0.35). This may imply that post-exposure prophylaxis is not effective in preventing symptomatic infection among patients who are exposed to known COVID-19-positive infections.

The FDA decided to retract emergency use authorization of these drugs on 15 June 2020. The basis of this decision is that hydroxychloroquine or chloroquine are unlikely to be effective in treating COVID-19, above and beyond the serious cardiac adverse events and several newly reported cases of methemoglobinemia associated with the use of these drugs in COVID-19 patients \[[@CR147]\]. Additionally, earlier observations of decreased viral shedding with these drugs have not been consistently replicated. Preliminary results from the RECOVERY trial reported that hydroxychloroquine did not provide a significant difference in the primary endpoint of 28-day mortality---25.7% in the hydroxychloroquine arm and 23.5% in the usual-care arm (HR 1.11, 95% CI 0.98--1.26, *p* = 0.10) \[[@CR148]\]. In addition, there was no evidence of beneficial effects on hospital length of stay or the need for mechanical ventilation. Similarly, the ORCHID study, which evaluated the safety and effectiveness of hydroxychloroquine for the treatment of COVID-19 in hospitalized adults, was halted by the NIH due to the lack of evidence of efficacy \[[@CR149]\]. Moreover, a double-blind, randomized phase IIb Brazilian study by Borba et al. evaluated the efficacy and safety of two different chloroquine dosages as adjunctive therapy in hospitalized patients with severe COVID-19 \[[@CR150]\]. The 81 enrolled patients were randomized to receive either high-dose chloroquine (i.e. 600 mg twice daily for 10 days) or low-dose chloroquine (i.e. 450 mg twice daily on day 1 and once daily for 4 days). All patients received azithromycin, and some received oseltamivir. Interim analysis of the study revealed that the high-dose regimen was associated with more cardiac toxic effects (QTc \> 500 ms, 18.9% vs. 11.1%) and death (39% vs. 15%), although the high-dose arm included more patients susceptible to cardiac complications. Thus, the high-dose regimen should not be recommended for the treatment of severe COVID-19, particularly in patients also receiving azithromycin and oseltamivir. The study continues to evaluate the low-dose regimen.

Colchicine {#Sec21}
----------

Colchicine is a potent oral anti-inflammatory medication that is indicated for the treatment of gout, familial Mediterranean fever, and pericarditis (off-label) \[[@CR151]\]. Colchicine exhibits anti-inflammatory properties by inhibiting the polymerization of microtubes, and possibly through effects on cellular adhesion molecules and inflammatory chemokines \[[@CR152]\]. Additionally, colchicine displays direct anti-inflammatory and immunomodulatory effects by inhibiting the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome and proinflammatory cytokines \[[@CR153]\]. Given the important role of inflammation in severe COVID-19, colchicine may play a role in mitigating the cytokine storm and limiting multiorgan damage. However, a retrospective study of 14,520 patients based on a large healthcare computerized database found no significant difference in the rates of colchicine use between patients with a positive RT-PCR result for SARS-CoV-2 and those with a negative result (0.53% vs. 0.48%) \[[@CR153]\]. This suggests that colchicine may not have a protective role against a SARS-CoV-2 infection. It has also been hypothesized that colchicine may be harmful in COVID-19 patients \[[@CR154]\]. At therapeutic doses, colchicine may decrease the release of surfactants by affecting alveolar type II pneumocytes. At toxic doses, colchicine may further inhibit surfactant secretion, worsen ARDS, and cause multiorgan failure and disseminated intravascular coagulation.

COLCORONA is a randomized, double-blind, placebo-controlled trial that is currently evaluating the efficacy and safety of colchicine in adult COVID-19 patients who have at least one high-risk criterion (NCT04322682). The trial aims to enroll 6000 newly diagnosed patients and will assess the impact of colchicine treatment on rates of hospitalization or death from the syndrome 30 days after enrollment. Patients will receive colchicine 0.5 mg twice daily for the first 3 days and then once daily for the remaining 27 days. Other trials are underway or planned (NCT04350320, NCT04326790, NCT04322565).

See Table [1](#Tab1){ref-type="table"} for a summary of the various pharmaco-immunomodulatory drugs.Table 1Summary of immunomodulatory agents for the management of COVID-19TreatmentsDosing regimens under investigationRoute of administration under investigationMode of actionCommon adverse eventsContraindications (US labeling)Major drug interactionsUse in specific populations*Specific immunomodulators*AnakinraIV: 100 mg every 6 h (total daily dose: 400 mg) for 15 days; 200 mg every 8 h for 7 days; 300 mg od for 4 days, followed by 100 mg odSC: 100 mg od for 10 or 28 days. Alternative regimen: 100 mg every 12 h on days 1--3, then 100 mg od from days 4--10IV, SCNote: IV route is currently not FDA-approvedAnti-cytokine, IL-1 receptor antagonistInjection site reactions, upper respiratory tract infections, headache, nausea, diarrhea, sinusitis, flu-like symptoms, abdominal painKnown hypersensitivity to *Escherichia coli*-derived proteins, anakinra, or any component of the productAvoid use with anti-TNF agents due to higher rates of infections and neutropeniaUse caution in the elderly due to higher rates of infections in the elderly populationIn patients with CrCl \< 30 and ESRD, use extended dosing intervals (every other day)Tocilizumab4--8 mg/kg (maximum single dose: 800 mg), may repeat after 12 hIVNo trials evaluating the SC formAnti-cytokine, IL-6 receptor antagonistInjection site reactions, upper respiratory tract infections (including tuberculosis), nasopharyngitis, headache, hypertension, increased ALT, hematological effectsKnown hypersensitivity to tocilizumabMay decrease serum concentration of CYP3A4 substratesSafety during pregnancy and lactation is unknownSarilumabNot describedIVNote: IV route is currently not FDA-approvedAnti-cytokine, IL-6 receptor antagonistNeutropenia, increased ALT, injection site erythema, upper respiratory infections, urinary tract infectionsKnown hypersensitivity to sarilumab or any of its inactive ingredientsMay decrease serum concentration of CYP3A4 substratesSafety during pregnancy and lactation is unknownRuxolitinibVarious regimens under investigation5 mg bid for 14 days; 10 mg bid; 2 × 10 mg bid dose at day 1 and can be increased up to 2 × 15 mg bid from day 2 to day 28; 5 mg bid from day 1 to day 3 then 10 mg bid from day 4 to day 10; 10 mg bid, for 14 days followed by 5 mg bid for 2 days and 5 mg od for 1 dayPOAnti-cytokine, JAK1/JAK2 inhibitorThrombocytopenia, neutropenia, anemia, infections, edema, headache, dizzinessNoneCYP3A4 substrate. Serum roxulitinib levels may increase when used with CYP3A4 inhibitors (i.e. ritonavir)Use in pregnant and lactating women is not recommendedMay require starting dose reduction in hepatic and renal impairmentBaricitinib2 or 4 mg od for 14 daysPOAnti-cytokine, JAK1/JAK2 inhibitorUpper respiratory tract infections, nausea, herpes simplex, herpes zosterNoneSubstrate of BCRP/ABCG2, CYP3A4, OAT1/3, P-gp/ABCB1Avoid use with strong OAT3 inhibitorsAvoid use in patients with severe hepatic impairment, and in patients with moderate or severe renal impairmentAdalimumabNot describedInjection, specifics not describedAnti-cytokine, anti-TNFαUpper respiratory tract infections, sinusitis, increased macrophage-dependent infection, tuberculosis, opportunistic infections, injection site reactions, increased creatine phosphokinase, headache, rashNoneAvoid use with anakinra due to higher rates of infections and neutropeniaUse with caution in patients with heart failure or decreased left ventricular function; may cause myocardial toxicity or exacerbate underlying myocardial dysfunctionUse caution in elderly patients; may increase infection riskSargramostim125 μg bid for 5 daysNebulized inhalationRecombinant humanized GM-CSFFever, hypertension, edema, pericardial effusion, chest pain, peripheral edema, tachycardia, central nervous system effects, dermatologic effects, endocrine and metabolic changes, GI effects, urinary tract infections, hyperbilirubinemia, neuromuscular and skeletal effects, retinal hemorrhage, increased serum creatinine, pharyngitis, epistaxis, dyspnea^a^Hypersensitivity to human GM-CSF, yeast-derived products, or any component of the formulationMay enhance myeloproliferative effects when administered with products that induce myeloproliferation (e.g. corticosteroids)Use with caution in patients with pre-existing cardiac disease; may cause supraventricular arrhythmiaSafety during pregnancy and lactation is unknownGimsilumab (investigational molecule)High dose on day 1 and low dose on day 8, specifics not describedIVAnti-GM-CSFNot describedNot describedNot describedNot describedConvalescent plasmaOne or two infusions. Titer depends on donorIVNeutralizing antibodies provide short-term passive immunityInadvertent transmission of infectious agents, allergic reactions, thrombotic complications, transfusion-associated circulatory overload, transfusion-related acute lung injuryAllergy to human plasma, sodium citrate, methylene blueIgA-deficient patients with antibodies to IgA and a history of hypersensitivityNoneNot recommended in patients with heart failure, chronic kidney failure in the dialysis phase, and organ transplant*Non-specific immunomodulators*IVIG0.3--0.5 g/kg daily for 5 daysIVAntibodies from pooled plasma provide short-term passive immunityHeadache, nausea, fever, chills, dyspnea, cough, sore throat, malaise, myalgia, arthralgia, abdominal pain, leukopenia, aseptic meningitis, infections, acute renal failure, stroke, myocardial infarction, deep vein thrombosis, pulmonary embolism, anaphylactic shockHistory of anaphylactic or severe systemic reaction to human immune globulinPatients with hyperprolinemia; IVIG contains stabilizer L-prolineIgA-deficient patients with antibodies to IgA and a history of hypersensitivityLive virus vaccines (measles, mumps, rubella, varicella)Use with caution in elderly patients; may be at higher risk for renal failure and thromboembolic events. Administer the minimum dose at the lowest infusion rate practicalDexamethasoneRECOVERY trial: 6 mg daily for 10 days; DEXA-COVID19 trial: 20 mg od from day 1 to day 5, followed by 10 mg od from day 6 to day 10IV or POProvide anti-inflammatory and antifibrotic effects to prevent extended cytokine responseSodium and water retention (less than methylprednisolone), hypertension, hyperglycemia, osteoporosis, cardiac hypertrophy, edema, hypokalemia, bruising, diaphoresis, urticaria, allergic rash, euphoria, psychosis, infections, myasthenia gravisHypersensitivity to corticosteroids or any component of the formulation, systemic fungal infectionSubstrate of CYP3A4 and P-gp/ABCB1. Live or attenuated virus vaccines (if using immunosuppressive doses of corticosteroids)Use with caution in the elderly with the smallest possible effective dose for the shortest durationMethylprednisolone0.5--1 mg/kg daily or 1--2 mg/kg daily (of methylprednisolone or equivalent) have been proposedHigher doses (cytokine storm): 60--125 mg (methylprednisolone) every 6 h for up to 3 daysIVProvide anti-inflammatory and antifibrotic effects to prevent extended cytokine responseSodium and water retention, hypertension, hyperglycemia, osteoporosis, cardiac hypertrophy, edema, hypokalemia, bruising, diaphoresis, urticaria, allergic rash, euphoria, psychosis, infections, myasthenia gravisHypersensitivity to corticosteroids or any component of the formulation, systemic fungal infectionCYP3A4 substrateLive or attenuated virus vaccines (if using immunosuppressive doses of corticosteroids)Use with caution in the elderly, with the smallest possible effective dose for the shortest durationNote: Oral corticosteroids should be continued in COVID-19 patients with an underlying condition (e.g. primary or secondary adrenal insufficiency, rheumatologic diseases)Inhaled corticosteroids should be continued in COVID-19 patients with asthma and COPDCorticosteroid treatment in pregnant women should be individualized; benefits should be weighed with potential harmInterferon-β-1b0.25 mg (8 million units) for 3 days; days 1, 2, 3, or days 1, 3, 5SCAntiviral and immunomodulatorPeripheral edema, skin rash, abdominal pain, urinary urgency, leukopenia, lymphocytopenia, neutropenia, increased ALT, injection site reaction, ataxia, chills, headache, hypertonia, insomnia, asthenia, myalgia, flu-like symptoms, feverHistory of hypersensitivity to natural or recombinant interferonβ, albumin (human), or any component of the formulationNo formal drug interaction studies have been conductedUse with caution in patients with bone marrow suppression, cardiovascular disease, hepatic impairmentInterferon-α-2b5 million units bidNebulizedAntiviral and immunomodulatorSkin rash, abdominal pain, leukopenia, lymphocytopenia, neutropenia, increased ALT, injection site reaction, ataxia, chills, headache, hypertonia, insomnia, asthenia, myalgia, flu-like symptoms, fever, hemolytic anemiaHypersensitivity to interferon-α or any component of the formulation, decompensated liver disease, autoimmune hepatitisNot fully evaluatedUse with caution in patients with a history of neuropsychiatric, autoimmune, ischemic, infectious disorders, and patients with pre-existing heart disease and organ transplant*Miscellaneous*StatinsSimvastatin 40 mg od for 14 days, simvastatin 80 mg od, atorvastatin 40 mg odPOAnti-inflammatory and immunomodulatory effectsHepatotoxicity, myopathies, GI effects, rhabdomyolysis, increased risk of diabetesHypersensitivity to statin or any component of the formulation, active liver disease; unexplained persistent elevations of serum transaminases; pregnancy, breastfeedingInhibitors/substrates of CYP3A4 may increase statin concentrationsUse with caution in elderly patients; may be at higher risk for myopathyStatins may need to be withheld for a short time period in COVID-19 patients with severe rhabdomyolysisACEi/ARBVarious dosing regimens: telmisartan 80 mg bid, telmisartan 40 mg bid, ramipril 2.5 mg od for 14 days, losartan 100 mg od, valsartan 80 or 160 mg for 14 days (max: 160 mg bid), captopril 25 mg, losartan 25 mg od, losartan 50 mg odPOAnti-inflammatory and immunomodulatory effectsCough (more common with ACEi), hyperkalemia, edema, angioedema (more common with ACEi), photosensitivity, renal failure, dysgeusia, headachePrevious angioneurotic edema (ACEi), pregnancy, hyperkalemia, bilateral renal stenosis, pregnancyRisk of hyperkalemia may be increased when combined with potassium-increasing medicationsTreatment should be continued in COVID-19 patients with an indication for ACEi/ARB; abrupt withdrawal may lead to clinical instabilityAzithromycin500 mg on day 1, then 250 mg od on days 2--5 in conjunction with a 10-day regimen of hydroxychloroquinePOAnti-inflammatory and immunomodulatory effectsQTc prolongation and ventricular arrhythmias, diarrhea, nausea, abdominal pain, vomitingHypersensitivity to azithromycin or other macrolides, history of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin useInhibits P-gp/ABCB1Elderly patients may be more susceptible to development of Torsades de pointes arrhythmiasHydroxychloroquine400 mg bid on day 1, then 200 mg bid on days 2--5; 400 mg od for 5 days; 200 mg tid for 10 days; 100--200 mg bid for 5--14 daysPOAnti-inflammatory and immunomodulatory effectsQTc prolongation, abdominal pain, decreased appetite, diarrhea, nausea, vomiting, hemolysis in G-6-PD deficiency, hypoglycemia, retinopathy, nervous system disorders, psychiatric disordersKnown hypersensitivity to hydroxychloroquine, 4-aminoquinoline derivatives, or any component of the formulationCYP2D6, CYP2C8, CYP3A4, CYP3A5Coadministration of chloroquine phosphate or hydroxychloroquine sulfate and remdesivir may result in reduced antiviral activity of remdesivirCaution should be exercised when administering to pregnant and nursing mothersColchicine0.5 mg bid for 3 days, then 0.5 mg od for 27 daysPOAnti-inflammatory and immunomodulatory effectsGI symptoms (diarrhea, nausea, vomiting, abdominal pain), neuromuscular toxicity, hematological effects, elevated AST and ALTRenal or hepatic impairment in conjunction with drugs that inhibit both CYP3A4 and P-gp (e.g. clarithromycin)Substrate of CYP3A4, P-gp/ABCB1Dose adjustment of colchicine is required in patients taking protease inhibitors (e.g. lopinavir/ritonavir)Dose adjustment is required in patients with renal or hepatic function*ACEi* angiotensin-converting enzyme inhibitors, *ALT* alanine aminotransferase, *ARB* angiotensin II receptor blockers, *AST* aminotransferase, *bid* twice daily, *COPD* chronic obstructive pulmonary disease, *COVID-19* coronavirus disease 2019, *CrCl* creatinine clearance, *CYP* cytochrome P450, *ESRD* end-stage renal disease, *G-6-PD* glucose-6-phosphate dehydrogenase, *GI* gastrointestinal, *GM-CSF* granulocyte--macrophage colony-stimulating factor, *IgA* immunoglobulin A, *IL* interleukin, *IV* intravenous, *IVIG* intravenous immunoglobulin, *JAK* Janus kinase, *max* maximum, *OAT* organic anion transporter, *od* once daily, *P-gp* P-glycoprotein, *PO* oral, *SC* subcutaneous, *tid* three times daily, *TNF* tumor necrosis factor^a^Reported with the IV and SC forms of the drug

Conclusion {#Sec22}
==========

COVID-19 is increasingly being recognized as a syndrome of viral replication and host inflammatory response. Effective pharmaco-immunomodulating strategies may help alleviate syndrome progression, especially in the more advanced stages of COVID-19. Considering the immune dysfunction and lymphopenia in COVID-19, several immunomodulators are under development or are being repurposed \[[@CR155]--[@CR157]\]. One plausible target is prostaglandin D2 (PGD2), which is normally upregulated in the airways of the elderly population, and is further augmented by SARS-CoV RNA, which stimulates the promoter of the cyclooxygenase (COX) genes. PGD2 is likely to play an important role in suppressing the host immune response to the virus by acting through the DP2 (CRTH2) receptor. In SARS-CoV-infected mice, PGD2 is reported to increase by two- to fivefold in the airways, and gradually increases with age \[[@CR158]\]. PGD2 signaling through DP2 stimulates group 2 innate lymphoid cells (ILC2s) to secrete IL-13, which in return activates monocytic myeloid-derived suppressor cells (M-MDSC) to suppress the adaptive immune system \[[@CR159]\]. MDSCs' mediated impairment of pathogen-specific adaptive immune responses have been demonstrated with *Hemophilus influenzae* respiratory infection \[[@CR160]\]. Furthermore, ILC2s, despite their scarcity, are the dominant innate lymphoid cell population in the lung, indicating a key role as first responders and amplifiers upon immune challenge at this site \[[@CR161]\]. Targeting PGD2/DP2 signaling holds potential as an immunotherapeutic approach for immune dysfunction and lymphopenia, characteristic features of COVID-19 disease. Ramatroban (Baynas^®^) is a potent, reversible, and selective antagonist of PGD2/DP2 receptors that has been shown to inhibit PGD2-stimulated IL-13 secretion, with a half maximal inhibitory concentration (IC~50~) of 118 nM \[[@CR162]--[@CR164]\]. It has a well-established safety profile and has been used orally as a treatment for allergic rhinitis in Japan for the past 20 years. Hence, clinical trials investigating the role of ramatroban as a therapeutic agent in the context of COVID-19 are warranted.

With such novel targeted therapies in the pipeline, more options may become available for the treatment of COVID-19. Recent studies have demonstrated that hydroxychloroquine and chloroquine may not be effective in treating COVID-19, and the known and potential benefits of these drugs do not outweigh their known and potential risks. However, low-dose dexamethasone (6 mg once daily, orally or intravenously, for 10 days) has been shown to be effective in reducing deaths by one-third in patients on mechanical ventilation and by one-fifth in patients receiving oxygen only. Future research efforts should focus not only on the most relevant immunomodulatory strategies but also the optimal timing of such immunomodulatory interventions to maximize therapeutic effect.
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